about
The second transmembrane domain of the human type 1 angiotensin II receptor participates in the formation of the ligand binding pocket and undergoes integral pivoting movement during the process of receptor activationMutational analysis of the conserved Asp2.50 and ERY motif reveals signaling bias of the urotensin II receptorExpression of the five somatostatin receptor (SSTR1-5) subtypes in rat pituitary somatotrophes: quantitative analysis by double-layer immunofluorescence confocal microscopyCD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heartMolecular cloning of a ferret angiotensin II AT(1) receptor reveals the importance of position 163 for Losartan binding.Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis.Biosensing based on surface plasmon resonance and living cells.Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model.New enzyme-activated solubility-switchable contrast agent for magnetic resonance imaging: from synthesis to in vivo imaging.Analysis of transmembrane domains 1 and 4 of the human angiotensin II AT1 receptor by cysteine-scanning mutagenesis.GPR103b functions in the peripheral regulation of adipogenesis.A polyaromatic caveolin-binding-like motif in the cytoplasmic tail of the type 1 receptor for angiotensin II plays an important role in receptor trafficking and signaling.Determining the environment of the ligand binding pocket of the human angiotensin II type I (hAT1) receptor using the methionine proximity assay.S-nitrosylation of cysteine 289 of the AT1 receptor decreases its binding affinity for angiotensin IIBiological properties and functional determinants of the urotensin II receptor.Constitutive activation of the angiotensin II type 1 receptor alters the spatial proximity of transmembrane 7 to the ligand-binding pocket.Functional effects of caloxin 1c2, a novel engineered selective inhibitor of plasma membrane Ca(2+)-pump isoform 4, on coronary artery.Ascorbic acid decreases the binding affinity of the AT1 receptor for angiotensin II.Substance P--structure-activity studies and the development of antagonists.Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues.The constitutively active N111G-AT1 receptor for angiotensin II modifies the morphology and cytoskeletal organization of HEK-293 cells.Involvement of a cytoplasmic-tail serine cluster in urotensin II receptor internalization.Identification of Distinct Conformations of the Angiotensin-II Type 1 Receptor Associated with the Gq/11 Protein Pathway and the β-Arrestin Pathway Using Molecular Dynamics Simulations.Tachykinin receptors in smooth muscles: a study with agonists (substance P, neurokinin A) and antagonists.Photolabelling the rat urotensin II/GPR14 receptor identifies a ligand-binding site in the fourth transmembrane domain.Activation induces structural changes in the liganded angiotensin II type 1 receptor.Identification of transmembrane domain residues determinant in the structure-function relationship of the human platelet-activating factor receptor by site-directed mutagenesis.Agonists for the Chemokine Receptor CXCR4.Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor.The fifth transmembrane domain of angiotensin II Type 1 receptor participates in the formation of the ligand-binding pocket and undergoes a counterclockwise rotation upon receptor activation.Photolabelling the urotensin II receptor reveals distinct agonist- and partial-agonist-binding sites.Temperature dependent photolabeling of the human angiotensin II type 1 receptor reveals insights into its conformational landscape and its activation mechanism.A single-nucleotide polymorphism of alanine to threonine at position 163 of the human angiotensin II type 1 receptor impairs Losartan affinity.The amino-terminus of angiotensin II contacts several ectodomains of the angiotensin II receptor AT1.Inhibition of endothelin-converting enzyme for protection against neointimal proliferation following balloon angioplasty of the rat carotid artery.Residues 293 and 294 are ligand contact points of the human angiotensin type 1 receptor.Methionine proximity assay, a novel method for exploring peptide ligand-receptor interaction.Identification of transmembrane domain 6 & 7 residues that contribute to the binding pocket of the urotensin II receptor.Substance P antagonists showing some selectivity for different receptor types.Tachykinin antagonists: substitutions in positions 5 and 6 with amino acids from the primary sequence of substance P homologues.
P50
Q24654927-647A7240-15BA-43CB-BD2E-CCB00DE9D337Q28281803-7724066B-0551-4838-A401-D842EA0BFB12Q28571964-32FA10B4-EF43-4D43-B7A9-7EDB523E55F3Q28647624-064C1EF4-2F5F-4C30-8DD3-E8BBCE672A82Q30875084-11C10FA0-E631-42E9-A0CF-64D8051FF81EQ32078607-362DD715-D47D-4E54-8398-BE4D77EA81A9Q33374949-FA452C7C-3120-484F-AC6A-E0ED1CF8916AQ33379851-F2562C5C-DD76-4C96-B640-3770DC741C12Q33410594-85724799-F432-46D5-9DFC-644DEAFD5E8FQ33593826-6795A4B9-4D8B-4DA9-8C1F-02FCCA0522CAQ33637436-51AB746E-A4AF-4186-9566-AA3D6CCEB601Q34160371-843C9F88-E080-44CB-9E9B-3FA00BB26E15Q34418452-1CCAEAC7-EA09-463A-A1E3-6EC8663C1F4FQ35545900-9BC553EC-DB4F-4A7A-8E28-77D72097A9CAQ37043921-29C2ECBE-90A3-492D-BDDA-1B777CF89E8AQ38352900-9BF30FE3-89BC-4661-87AE-75547A0BF537Q39737608-5E99C6D3-3757-4763-A9F6-B2B58B9F83D4Q40033396-13FB6D55-A26C-49A4-BE35-5FEB2F2FEDD0Q40110142-4C59EEEF-E395-431A-8591-47E4721075BEQ40349088-4F512461-3D00-4E6D-BA3B-0CEC18DEE4D6Q40421874-E576781E-4D82-420D-B111-8003791C973CQ40509065-6CBB0D59-20EA-4AC6-A800-1DFB489C8E80Q41774393-4171825D-C4B3-4028-B376-C117AFF7749FQ41856571-730AB4C4-34E7-4D79-A434-37F4EF7D9323Q41981084-AC3CA513-9D89-4EF0-BD85-69FFD8D1BEEAQ42457570-B9034E49-5BB4-45CC-9C3A-314B4E131233Q42554177-BF31AABB-58D8-41A3-9146-B8CEF0936400Q42738899-04E8B545-56A1-4D7A-98DA-937D2FF63406Q42912360-D1728163-B156-4ABF-8F98-EE2208BE43D0Q42948753-8D9385CD-D793-421F-AD68-2947889B2B26Q42976039-744892C6-F925-4153-89AA-F98F665356C7Q42989696-53A85689-2FE3-416F-97AF-5DCBF950AFE8Q43076864-11144A08-69D3-4DC2-B836-CBDCF980AD0AQ43166345-C441C95D-DCAB-4487-90CF-D0430D714409Q44022120-39CBA8C3-A431-4364-9915-EDC25F3A8E73Q44228096-A4554916-2E68-43D2-85C0-BE9BCB95CD81Q44263337-DB6F9C57-07B7-4588-AFB7-C0E007BB17ACQ46019919-F1D3FD4C-D407-4FEB-9F7D-1B88BB162ABBQ46143344-AC3F9888-AE0B-496D-B9D2-949ECD024B67Q46475998-4B1B630E-33D1-4DA1-9191-2B2FFE52A651
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Emanuel Escher
@ast
Emanuel Escher
@en
Emanuel Escher
@es
Emanuel Escher
@nl
Emanuel Escher
@sl
type
label
Emanuel Escher
@ast
Emanuel Escher
@en
Emanuel Escher
@es
Emanuel Escher
@nl
Emanuel Escher
@sl
prefLabel
Emanuel Escher
@ast
Emanuel Escher
@en
Emanuel Escher
@es
Emanuel Escher
@nl
Emanuel Escher
@sl
P106
P1153
7005259199
P21
P31
P496
0000-0001-6601-987X